Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,433 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Completed Phase 3 Interventional

Improving Neurologic Outcomes in People With Diabetes Who Are Undergoing Heart Surgery

NCT00836329
View directory record Official record
Conditions
Diabetes Mellitus, Cardiovascular Diseases
Interventions
Intensive Glucose Management, Traditional Glucose Management:
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
35 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

NCT03188965
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Elimusertib (BAY1895344)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 24, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

NCT00557830
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Sorafenib Escalated Dose, Sorafenib Standard Dose
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Jonesboro, Arkansas • La Verne, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 24, 2026, 5:06 PM EDT
Withdrawn Not applicable Interventional

Exercise and Nutritional Intervention for Deconditioned Older Adults

NCT01115530
View directory record Official record
Conditions
Muscle Weakness
Interventions
Resistance exercise, Protein and HMB (see below) supplement
Other · Dietary Supplement
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years to 90 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
No. Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 24, 2026, 5:06 PM EDT
Completed No phase listed Observational

Study of Ultrasound of the Eye for Children With Suspected Shunt Failure

NCT00743457
View directory record Official record
Conditions
Hydrocephalus
Interventions
Ocular Ultrasound
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 24, 2026, 5:06 PM EDT
Completed No phase listed Observational

Short Term Pancreatic Stenting Registry

NCT02262845
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis, Pancreatic Duct Stricture, Pancreatic Duct Stones, Pancreatic Duct Leakage
Interventions
The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

NCT00861328
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 24, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia

NCT02508324
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
haplo-identical cells (donor), umbilical cord blood unit (CBU)
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 2Phase 3 Interventional

Enhanced Recovery After Surgery in Orthopaedic Spine Surgery

NCT04562610
View directory record Official record
Conditions
Lumbar Surgery
Interventions
Intravenous Infusion group, All oral administration group
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 105 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

NCT02833389
View directory record Official record
Conditions
Neuropathic Diabetic Foot Ulcers
Interventions
Placebo, UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • San Francisco, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 24, 2026, 5:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

NCT07095868
View directory record Official record
Conditions
Selected Types of Solid Tumor
Interventions
EVM14, Pembrolizumab
Biological · Combination Product
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View directory record Official record
Conditions
HIV-1-infection
Interventions
PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
Biological · Device
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 24, 2026, 5:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
UCART20x22, CLLS52
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

NCT04776317
View directory record Official record
Conditions
COVID-19
Interventions
ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 24, 2026, 5:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lipid Screening Study

NCT07579325
View directory record Official record
Conditions
Lipoprotein (a)
Interventions
Venipuncture
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 5:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

NCT01998035
View directory record Official record
Conditions
Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions
RomiDEPsin 10 MG/M2, Oral 5-Azacitidine 100 MG, Romidepsin 14 MG/M2, Oral 5-Azacitidine 200 MG, Oral 5-Azacitidine 300 MG
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

NCT02657343
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, T-DM1, Trastuzumab, Fulvestrant
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Results available

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

NCT02569476
View directory record Official record
Conditions
B-cell Lymphoid Malignancies
Interventions
Zanubrutinib, Obinutuzumab
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Fort Myers, Florida • West Palm Beach, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

NCT02280525
View directory record Official record
Conditions
Leukemia
Interventions
Lenalidomide, Rituximab, Fludarabine, Cyclophosphamide, NK Cells, Cytarabine
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 24, 2026, 5:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Age on Cardiovascular, Cerebrovascular and Cognitive Health in Spinal Cord Injury

NCT01984476
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Not listed
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
25 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 24, 2026, 5:06 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Modeling, Optimization, and Control Methods for a Personalized Hybrid Walking Exoskeleton

NCT04453943
View directory record Official record
Conditions
Spinal Cord Injuries, Paraplegia, Spinal, Paraplegia, Incomplete
Interventions
Exoskeleton Walking - with or without FES, Exoskeleton Sitting to Standing - with or without FES
Device
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

NCT04765449
View directory record Official record
Conditions
Covid19
Interventions
Cytotoxic T Lymphocytes
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 24, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

NCT03905148
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Lifirafenib, mirdametinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Santa Monica, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 24, 2026, 5:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

NCT07284433
View directory record Official record
Conditions
Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
Interventions
Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T
Other · Drug
Lead sponsor
AvenCell Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Chicago, Illinois • Evanston, Illinois • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 24, 2026, 5:06 PM EDT